Degrading JAK2 in ALL by ruxolitinib-based PROTACs.
(2021) Blood — Vol. 138, n° 23, p. 2301-2302 (2021)
Files
44ConstantinescuetalBlood2021.pdf
Open Access - Adobe PDF
- 612.73 KB
Details
- Authors
- Abstract
- (en) In this issue of Blood, Chang et al report the successful targeting JAK2 for degradation in cytokine receptor–like factor 2 (CRLF2)-rearranged acute lymphoblastic leukemia (ALL). [...]
- Affiliations
Citations
Constantinescu, S., & Pecquet, C. (2021). Degrading JAK2 in ALL by ruxolitinib-based PROTACs. Blood, 138(23), 2301-2302. https://doi.org/10.1182/blood.2021012004 (Original work published 2021)